Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles…
- Investigator
- Joanne Lagmay
- Status
- Accepting Candidates
- Ages
- 12 Months - 21 Years
- Sexes
- All
Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
- Investigator
- Joanne Lagmay
- Status
- Accepting Candidates
- Ages
- 12 Years - 99 Years
- Sexes
- All
Neuroblastoma Maintenance Therapy Trial (NMTT)
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ±…
- Investigator
- Joanne Lagmay
- Status
- Accepting Candidates
- Ages
- 1 Year - 30 Years
- Sexes
- All